Shareholding Pattern Q1 2022-23
Shareholding Pattern Q1 2021-22
Shareholding Pattern Q2 2021-22
Shareholding Pattern Q3 2021-22
Shareholding Pattern Q4 2021-22
Shareholding Pattern Q1 2020-21
Shareholding Pattern Sep 30 2020
Shareholding Pattern Q3 Dec 31 2020
Shareholding Pattern Q4 2021
Shareholding Pattern Q1 2019-20
Shareholding Pattern Q2 FY 2020
Shareholding Pattern Q3 2019-20
Shareholding Pattern Q4 2019-20
Shareholding Pattern Q1 2018-19
Shareholding Pattern Q2 2018-19
Shareholding Pattern Q3 2018-19
Shareholding Pattern Q4 2018-19
Shareholding Pattern Q1 2017-18
Shareholding Pattern Q2 2017-18
Shareholding Pattern Q3 2017-18
Shareholding Pattern Q4 2017-18
Q3-Shareholding Pattern
Shareholding Pattern Q4 2016-17
Unclaimed Dividend FY 2021-22 Interim
Unclaimed Dividend FY 2021-22 2nd Interim
Unclaimed Dividend FY 2020-21 Interim
Unclaimed Dividend FY 2020-21 3rd Interim
Unclaimed Dividend FY 2020-21 2nd Interim
Unclaimed Dividend FY 2019-20 Interim
Unclaimed Dividend FY 2019-20 FINAL
Unclaimed_Dividend_FY_2018-19
Unclaimed Dividend FY 2017-18
Unclaimed Dividend FY 2016-17
We are building on our strengths to further extend our product portfolio and target fast-growing segments.
As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases.
As a responsible corporate citizen, we will conduct our business with complete respect for the environment and community.
Laurus Synthesis 
Laurus Generics GmbH 
Laurus Generics Inc. 
